Blood Cancer Discovery, May 02, 2025

We recently wrote a review on overcoming resistance to targeted and immune therapies in B-cell acute lymphoblastic leukemia (B-ALL), highlighting rational combination strategies aimed at improving patient outcomes. The article emphasizes integration of targeted therapies, such as tyrosine kinase inhibitors and venetoclax, with immunotherapies like bispecific antibodies, antibody-drug conjugates, and CAR T-cells. It discusses mechanisms of resistance, including antigen escape and signalling pathway adaptations, and outlines novel combination approaches to enhance therapeutic efficacy and durability, significantly advancing translational hematology research

BioRxiv, Mar 31, 2025

In our recent preprint, we investigate the role of the NUP98-NSD1 fusion oncogene in pediatric acute myeloid leukemia (AML), demonstrating that its expression in human hematopoietic stem and progenitor cells leads to leukemic transformation. We further elucidate that the oncogenic potential of NUP98-NSD1 is influenced by the ontogeny of the cells, highlighting the importance of developmental context in leukemia pathogenesis.

Current Opinion in Hematology, Mar 01, 2025

We recently wrote a review on the diverse models used to study myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), highlighting their applications and limitations in understanding disease biology and testing therapies. The article focuses on genetically engineered mouse models, human iPSC-derived systems, patient-derived xenografts, and engineered blood stem cells, emphasizing their contributions to advancing translational hematology research.